ISLET Act
Organ Donation: Reclassifying Pancreas Cells for Transplants
The ISLET Act is currently in the early stages of the legislative process. It was recently introduced in the Senate and sent to the Committee on Health, Education, Labor, and Pensions for review. No further actions are scheduled at this time.
Part of: story →Legislative Progress
This bill is in the very early stages of the legislative process. While it addresses a specific medical need, it currently lacks the broad bipartisan support usually required to pass the Senate.
Key Points
- The ISLET Act changes the legal definition of certain pancreas cells used in transplants. Instead of being treated like manufactured drugs, these cells from deceased donors would be classified as human organs.
- This change is important for people with Type 1 diabetes who need islet transplants to manage their blood sugar. Treating the cells as organs could simplify the transplant process and help more patients get the treatment through the national organ sharing system.
- The bill gives the Department of Health and Human Services one year to rewrite its rules. This would move the oversight of these cells from the Food and Drug Administration to the agencies that manage organ donations like kidneys and hearts.
Impact Analysis
Govbase has not yet run an impact analysis on this legislation.
Milestones
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
News
No related news coverage found for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
ISLET Act
Data Sources
Sponsor
Cosponsors
(1)Analysis generated by AI. Always verify with official sources.